JP2022119852A5 - - Google Patents

Download PDF

Info

Publication number
JP2022119852A5
JP2022119852A5 JP2022081736A JP2022081736A JP2022119852A5 JP 2022119852 A5 JP2022119852 A5 JP 2022119852A5 JP 2022081736 A JP2022081736 A JP 2022081736A JP 2022081736 A JP2022081736 A JP 2022081736A JP 2022119852 A5 JP2022119852 A5 JP 2022119852A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
tautomer
stereoisomer
geometric isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022081736A
Other languages
English (en)
Japanese (ja)
Other versions
JP7384535B2 (ja
JP2022119852A (ja
Filing date
Publication date
Priority claimed from CN201611211589.5A external-priority patent/CN108239075B/zh
Priority claimed from CN201611214102.9A external-priority patent/CN108239076B/zh
Priority claimed from CN201611204309.8A external-priority patent/CN108239074B/zh
Priority claimed from JP2019534817A external-priority patent/JP7077323B2/ja
Application filed filed Critical
Publication of JP2022119852A publication Critical patent/JP2022119852A/ja
Publication of JP2022119852A5 publication Critical patent/JP2022119852A5/ja
Application granted granted Critical
Publication of JP7384535B2 publication Critical patent/JP7384535B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022081736A 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物 Active JP7384535B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201611211589.5A CN108239075B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611214102.9A CN108239076B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611214102.9 2016-12-26
CN201611204309.8A CN108239074B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611211589.5 2016-12-26
CN201611204309.8 2016-12-26
JP2019534817A JP7077323B2 (ja) 2016-12-26 2017-12-26 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
PCT/CN2017/118771 WO2018121550A1 (zh) 2016-12-26 2017-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019534817A Division JP7077323B2 (ja) 2016-12-26 2017-12-26 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Publications (3)

Publication Number Publication Date
JP2022119852A JP2022119852A (ja) 2022-08-17
JP2022119852A5 true JP2022119852A5 (cg-RX-API-DMAC7.html) 2022-11-09
JP7384535B2 JP7384535B2 (ja) 2023-11-21

Family

ID=62707834

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019534817A Active JP7077323B2 (ja) 2016-12-26 2017-12-26 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2022081736A Active JP7384535B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2022081738A Active JP7384536B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019534817A Active JP7077323B2 (ja) 2016-12-26 2017-12-26 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022081738A Active JP7384536B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Country Status (7)

Country Link
US (3) US11534443B2 (cg-RX-API-DMAC7.html)
EP (3) EP4169918B8 (cg-RX-API-DMAC7.html)
JP (3) JP7077323B2 (cg-RX-API-DMAC7.html)
CN (1) CN110382490A (cg-RX-API-DMAC7.html)
AU (3) AU2017389818B2 (cg-RX-API-DMAC7.html)
CA (3) CA3048546A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018121550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169918B8 (en) * 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
CN114555588B (zh) * 2019-11-07 2024-08-06 南京正大天晴制药有限公司 作为axl抑制剂的喹唑啉类化合物
CN113620976B (zh) * 2020-05-09 2023-09-26 中国医学科学院药物研究所 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
PE20231311A1 (es) 2020-11-18 2023-08-24 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
MX2024006627A (es) 2021-12-03 2024-08-22 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
TW202416953A (zh) * 2022-08-26 2024-05-01 日商衛材R&D企管股份有限公司 抗體藥物複合物
CA3223670C (en) 2023-03-30 2026-05-26 Sunstack, Llc Trestle

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008781B1 (ko) * 1993-08-05 1996-07-03 김하운 연소효율 증강장치
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
CN105283454B (zh) * 2013-04-12 2019-10-29 阿萨纳生物科技有限责任公司 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉
CN108239076B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
EP4169918B8 (en) * 2016-12-26 2025-09-24 Institute of Materia Medica, Chinese Academy of Medical Sciences Quinazoline derivatives as inhibitors of pi3k for the treatment of cancer
CN108239075B (zh) * 2016-12-26 2021-07-02 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239074B (zh) * 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物

Similar Documents

Publication Publication Date Title
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2024514837A5 (cg-RX-API-DMAC7.html)
JP2021523221A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2014532716A5 (cg-RX-API-DMAC7.html)
JP2013502431A5 (cg-RX-API-DMAC7.html)
JP2008510770A5 (cg-RX-API-DMAC7.html)
JP2004516314A5 (cg-RX-API-DMAC7.html)
CA2440037A1 (en) Benzimidazole derivatives for modulating the rage receptor
JP2022501429A5 (cg-RX-API-DMAC7.html)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2011516460A5 (cg-RX-API-DMAC7.html)
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
JP2011509301A5 (cg-RX-API-DMAC7.html)
RU2015135722A (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
CN1420776A (zh) 环氧合酶-2活性的抑制
JP2025500826A5 (cg-RX-API-DMAC7.html)
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2023549187A5 (cg-RX-API-DMAC7.html)
JP2024507414A5 (cg-RX-API-DMAC7.html)
JP2011526286A5 (cg-RX-API-DMAC7.html)
JP7296070B2 (ja) がん免疫療法アジュバント
RU2003130644A (ru) Производные ркарболина и их фармацевтическое применение против дипрессии и страха